Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Apple Turns 50: From Garage Startup to AI Crossroads 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant 
SAN DIEGO, Dec. 02, 2015 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that Charles Theuer, M.D, Ph.D., President and CEO, will present at the Oppenheimer 26th Annual Healthcare Conference at 2:10 pm EST on Wednesday, December 9, 2015, at the Westin Grand Central Hotel in New York, NY.
To access a live webcast of the presentation, please visit the “Events and Presentation” section within the “Investors” section of the TRACON Pharmaceuticals website at www.traconpharma.com. A replay of the webcast will be available on the website for 60 days following the event.
About TRACON
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The company’s clinical-stage pipeline includes two product candidates: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers and wet AMD through a collaboration with Santen Pharmaceutical Company Ltd., and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Company Contact: Investor Contact: Casey Logan Andrew McDonald Chief Business Officer LifeSci Advisors LLC (858) 550‐0780 ext. 236 646-597-6987 [email protected] [email protected]
